Cardiex Ltd
ASX:CDX
Intrinsic Value
CardieX Ltd. is engaged in the designing, manufacturing, and marketing of medical devices for use in cardiovascular health management. [ Read More ]
The intrinsic value of one CDX stock under the Base Case scenario is 0.306 AUD. Compared to the current market price of 0.076 AUD, Cardiex Ltd is Undervalued by 75%.
Valuation Backtest
Cardiex Ltd
Run backtest to discover the historical profit from buying and selling CDX stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Cardiex Ltd
Current Assets | 14.5m |
Cash & Short-Term Investments | 4.3m |
Receivables | 1.6m |
Other Current Assets | 8.6m |
Non-Current Assets | 2.3m |
Long-Term Investments | 369.7k |
PP&E | 1.3m |
Intangibles | 625.5k |
Other Non-Current Assets | 42.2k |
Current Liabilities | 14.2m |
Accounts Payable | 7.4m |
Accrued Liabilities | 502.1k |
Short-Term Debt | 1.5m |
Other Current Liabilities | 4.8m |
Non-Current Liabilities | 2.6m |
Long-Term Debt | 2.6m |
Other Non-Current Liabilities | 9.5k |
Earnings Waterfall
Cardiex Ltd
Revenue
|
12.9m
AUD
|
Cost of Revenue
|
-916k
AUD
|
Gross Profit
|
12m
AUD
|
Operating Expenses
|
-16.7m
AUD
|
Operating Income
|
-4.7m
AUD
|
Other Expenses
|
-4.7m
AUD
|
Net Income
|
-9.4m
AUD
|
Free Cash Flow Analysis
Cardiex Ltd
What is Free Cash Flow?
CDX Profitability Score
Profitability Due Diligence
Cardiex Ltd's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
Score
Cardiex Ltd's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
CDX Solvency Score
Solvency Due Diligence
Cardiex Ltd's solvency score is 35/100. The higher the solvency score, the more solvent the company is.
Score
Cardiex Ltd's solvency score is 35/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CDX Price Targets Summary
Cardiex Ltd
Shareholder Return
CDX Price
Cardiex Ltd
Average Annual Return | 15.74% |
Standard Deviation of Annual Returns | 77.53% |
Max Drawdown | -93% |
Market Capitalization | 14.7m AUD |
Shares Outstanding | 193 747 000 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
CardieX Ltd. is engaged in the designing, manufacturing, and marketing of medical devices for use in cardiovascular health management. The company is headquartered in Sydney, New South Wales. The company went IPO on 2005-11-09. The firm is focused on designing, manufacturing and marketing medical devices for use in cardiovascular health management. The company operates through its subsidiaries, including ATCOR and CONNEQT. The firm's ATCOR division provides medical devices for measuring arterial stiffness and central blood pressure waveforms based on its FDA-cleared and patented SphygmoCor technology. Under the ATCOR.X brand, the Company also develops and licenses its Arty platform consisting of physiological and health analytics for wearable devices. The firm's digital platform, ArtyNet, is a connected software as a service ecosystem providing physicians with a telehealth solution for remotely managing patients' health. CONNEQT develops and markets consumer wearable and home health devices focused on heart health and its patented fitness and wellness parameters.
Contact
IPO
Employees
Officers
The intrinsic value of one CDX stock under the Base Case scenario is 0.306 AUD.
Compared to the current market price of 0.076 AUD, Cardiex Ltd is Undervalued by 75%.